Agios Pharmaceuticals (AGIO) Stock Forecast, Price Target & Predictions
AGIO Stock Forecast
Agios Pharmaceuticals stock forecast is as follows: an average price target of $47.50 (represents a 1.73% upside from AGIO’s last price of $46.69) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
AGIO Price Target
The average price target for Agios Pharmaceuticals (AGIO) is $47.50 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $70.00 to $32.00. This represents a potential 1.73% upside from AGIO's last price of $46.69.
AGIO Analyst Ratings
According to 5 Wall Street analysts, Agios Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for AGIO stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Agios Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 10, 2024 | Chris Raymond | Raymond James | $56.00 | $44.05 | 27.13% | 19.94% |
| Jun 17, 2024 | Chris Raymond | Raymond James | $55.00 | $43.42 | 26.67% | 17.80% |
| Jun 03, 2024 | Gregory Renza | RBC Capital | $53.00 | $44.26 | 19.75% | 13.51% |
| May 28, 2024 | Chris Raymond | Raymond James | $45.00 | $38.39 | 17.22% | -3.62% |
| Feb 03, 2023 | - | Piper Sandler | $41.00 | $30.18 | 35.85% | -12.19% |
| Dec 01, 2022 | - | J.P. Morgan | $33.00 | $29.46 | 12.02% | -29.32% |
| Nov 17, 2022 | - | Goldman Sachs | $32.00 | $27.13 | 17.95% | -31.46% |
| Apr 30, 2021 | Peter Lawson | Barclays | $70.00 | $55.80 | 25.45% | 49.93% |
The latest Agios Pharmaceuticals stock forecast, released on Sep 10, 2024 by Chris Raymond from Raymond James, set a price target of $56.00, which represents a 27.13% increase from the stock price at the time of the forecast ($44.05), and a 19.94% increase from AGIO last price ($46.69).
Agios Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 4 |
| Avg Price Target | $56.00 | $55.50 | $52.25 |
| Last Closing Price | $46.69 | $46.69 | $46.69 |
| Upside/Downside | 19.94% | 18.87% | 11.91% |
In the current month, the average price target of Agios Pharmaceuticals stock is $56.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 19.94% increase as opposed to Agios Pharmaceuticals's last price of $46.69. This month's average price target is up 0.90% compared to last quarter, and up 7.18% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 10, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 03, 2024 | RBC Capital | Outperform | Outperform | Hold |
| May 28, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 28, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 27, 2023 | RBC Capital | Outperform | Outperform | Hold |
| Feb 03, 2023 | Piper Sandler | - | Overweight | Initialise |
| Nov 17, 2022 | Goldman Sachs | Sell | Neutral | Upgrade |
| Jul 27, 2022 | SVB Leerink | Market Perform | Outperform | Upgrade |
| May 24, 2022 | Goldman Sachs | Sell | Sell | Hold |
| Feb 25, 2022 | RBC Capital | Outperform | Outperform | Hold |
Agios Pharmaceuticals's last stock rating was published by Piper Sandler on Sep 10, 2024. The company gave AGIO a "Overweight" rating, the same as its previous rate.
Agios Pharmaceuticals Financial Forecast
Agios Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $7.40M | $6.71M | $5.61M | $4.31M | $3.52M | - | $832.00K | - | - | - | - | $44.05M | $34.71M | $37.35M | $87.10M | $35.44M | $26.02M | $26.22M | $30.23M | $30.01M | $15.20M |
| Avg Forecast | $31.50M | $14.80M | $13.25M | $11.85M | $11.14M | $9.91M | $9.34M | $8.37M | $7.92M | $7.53M | $6.46M | $5.24M | $4.54M | $5.27M | $2.91M | $2.71M | $614.70K | $2.55M | $2.49M | $47.23M | $39.86M | $38.12M | $37.14M | $31.12M | $33.72M | $33.13M | $27.01M | $22.69M | $31.72M | $15.10M |
| High Forecast | $40.73M | $19.14M | $17.13M | $15.32M | $14.40M | $10.25M | $12.08M | $10.82M | $10.24M | $8.69M | $8.36M | $6.78M | $5.86M | $6.81M | $2.91M | $4.01M | $908.13K | $3.77M | $3.68M | $69.77M | $58.89M | $56.32M | $54.87M | $45.98M | $49.82M | $48.95M | $39.90M | $33.52M | $38.07M | $18.13M |
| Low Forecast | $27.68M | $13.01M | $11.64M | $10.41M | $9.79M | $9.31M | $8.21M | $7.35M | $6.96M | $6.91M | $5.68M | $4.61M | $3.99M | $4.63M | $2.91M | $2.07M | $469.58K | $1.95M | $1.90M | $36.08M | $30.45M | $29.12M | $28.37M | $23.78M | $25.76M | $25.31M | $20.63M | $17.33M | $25.38M | $12.08M |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 3 | 6 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 8 | 5 | 5 | 10 | 7 | 4 | 4 | 8 | 5 | 11 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.98% | 1.04% | 1.07% | 0.95% | 0.67% | - | 0.31% | - | - | - | - | 1.11% | 0.91% | 1.01% | 2.80% | 1.05% | 0.79% | 0.97% | 1.33% | 0.95% | 1.01% |
Agios Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 3 analysts is $7.92M, with a low forecast of $6.96M, and a high forecast of $10.24M. AGIO's average Quarter revenue forecast represents a 7.07% increase compared to the company's last Quarter revenue of $7.40M (Sep 23).
Agios Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 3 | 6 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 8 | 5 | 5 | 10 | 7 | 4 | 4 | 8 | 5 | 11 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-100.90M | $-93.70M | $-90.61M | $-225.21M | $-93.55M | - | $-101.37M | $-92.09M | $-86.30M | $-83.96M | $1.88B | $-88.97M | $-86.81M | $-86.00M | $-34.85M | $-96.81M | $-101.20M | $-103.84M | $-86.67M | $-85.32M | $-88.37M |
| Avg Forecast | $-18.90M | $-8.88M | $-7.95M | $-7.11M | $-6.68M | $-5.95M | $-5.61M | $-83.18M | $-4.75M | $-4.52M | $-3.88M | $-88.96M | $-2.72M | $-108.11M | $-1.74M | $-95.14M | $267.62K | $-98.28M | $-92.83M | $-1.79B | $-83.61M | $-83.67M | $-89.76M | $-55.99M | $-107.39M | $-103.51M | $-97.05M | $-99.40M | $-94.73M | $-92.29M |
| High Forecast | $-16.61M | $-7.80M | $-6.99M | $-6.25M | $-5.87M | $-5.58M | $-4.93M | $-66.54M | $-4.18M | $-4.15M | $-3.41M | $-71.17M | $-2.39M | $-86.49M | $-1.74M | $-76.12M | $321.15K | $-78.63M | $-74.27M | $-1.43B | $-66.89M | $-66.93M | $-71.81M | $-44.80M | $-85.91M | $-82.81M | $-77.64M | $-79.52M | $-75.78M | $-73.83M |
| Low Forecast | $-24.44M | $-11.48M | $-10.28M | $-9.19M | $-8.64M | $-6.15M | $-7.25M | $-99.81M | $-6.15M | $-5.22M | $-5.01M | $-106.75M | $-3.52M | $-129.73M | $-1.74M | $-114.17M | $214.10K | $-117.94M | $-111.40M | $-2.15B | $-100.34M | $-100.40M | $-107.71M | $-67.19M | $-128.87M | $-124.22M | $-116.46M | $-119.28M | $-113.67M | $-110.75M |
| Surprise % | - | - | - | - | - | - | - | - | - | 22.34% | 24.16% | 1.02% | 82.76% | 0.87% | - | 1.07% | -344.11% | 0.88% | 0.90% | -1.05% | 1.06% | 1.04% | 0.96% | 0.62% | 0.90% | 0.98% | 1.07% | 0.87% | 0.90% | 0.96% |
3 analysts predict AGIO's average Quarter EBITDA for Jun 21 to be $-92.83M, with a high of $-74.27M and a low of $-111.40M. This is -104.95% lower than Agios Pharmaceuticals's previous annual EBITDA (Mar 21) of $1.88B.
Agios Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 3 | 6 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 8 | 5 | 5 | 10 | 7 | 4 | 4 | 8 | 5 | 11 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | $-91.32M | $-83.81M | $-71.42M | $172.22M | $-72.40M | - | $-88.40M | $-98.92M | $-88.77M | $-86.22M | $1.87B | $-97.66M | $-98.98M | $-90.48M | $-40.26M | $-102.35M | $-106.17M | $-109.87M | $-93.08M | $-91.79M | $-94.66M |
| Avg Forecast | $-80.09M | $-90.60M | $-95.81M | $-92.78M | $-100.54M | $-97.15M | $-90.98M | $-86.06M | $-93.60M | $-96.71M | $-88.68M | $-92.04M | $-77.76M | $-105.53M | $-98.48M | $-98.44M | $-93.04M | $-95.93M | $-88.08M | $37.81B | $-91.78M | $-95.39M | $-94.44M | $-59.66M | $-109.49M | $-105.58M | $-98.88M | $-101.59M | $-96.74M | $-94.08M |
| High Forecast | $-67.47M | $-76.32M | $-80.71M | $-78.16M | $-84.70M | $3.32B | $-76.64M | $-68.85M | $-78.85M | $-78.93M | $-74.71M | $-73.63M | $-65.50M | $-84.42M | $-98.48M | $-78.75M | $-64.49M | $-76.75M | $-70.46M | $45.38B | $-73.43M | $-76.31M | $-75.55M | $-47.73M | $-87.59M | $-84.47M | $-79.11M | $-81.27M | $-77.39M | $-75.26M |
| Low Forecast | $-110.59M | $-125.10M | $-132.29M | $-128.11M | $-138.83M | $-3.52B | $-125.63M | $-103.27M | $-129.24M | $-101.93M | $-122.45M | $-110.45M | $-107.37M | $-126.63M | $-98.48M | $-118.13M | $-150.78M | $-115.12M | $-105.69M | $30.25B | $-110.14M | $-114.47M | $-113.33M | $-71.59M | $-131.39M | $-126.70M | $-118.66M | $-121.91M | $-116.09M | $-112.90M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.94% | 0.95% | 0.78% | -2.21% | 0.69% | - | 0.90% | 1.06% | 0.93% | 0.98% | 0.05% | 1.06% | 1.04% | 0.96% | 0.67% | 0.93% | 1.01% | 1.11% | 0.92% | 0.95% | 1.01% |
Agios Pharmaceuticals's average Quarter net income forecast for Mar 23 is $-92.04M, with a range of $-110.45M to $-73.63M. AGIO's average Quarter net income forecast represents a -153.44% decrease compared to the company's last Quarter net income of $172.22M (Dec 22).
Agios Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 3 | 6 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 8 | 5 | 5 | 10 | 7 | 4 | 4 | 8 | 5 | 11 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | $25.82M | $30.41M | $28.37M | $32.77M | $29.12M | - | $31.52M | $31.53M | $27.15M | $29.21M | $33.55M | $39.78M | $34.84M | $35.95M | $38.50M | $34.83M | $33.02M | $32.39M | $31.79M | $31.86M | $31.10M |
| Avg Forecast | $99.97M | $46.97M | $42.05M | $37.61M | $35.35M | $31.45M | $29.65M | $26.56M | $25.14M | $23.88M | $20.51M | $16.64M | $14.39M | $16.72M | $9.22M | $8.61M | $-87.25K | $8.10M | $7.90M | $149.87M | $37.39M | $33.58M | $117.86M | $98.77M | $107.02M | $32.84M | $85.71M | $72.01M | $100.67M | $47.94M |
| High Forecast | $129.25M | $60.73M | $54.37M | $48.62M | $45.71M | $32.52M | $38.34M | $34.34M | $32.51M | $27.59M | $26.52M | $21.51M | $18.61M | $21.62M | $9.22M | $12.72M | $-69.80K | $11.97M | $11.67M | $221.42M | $44.86M | $40.29M | $174.12M | $145.92M | $158.11M | $39.40M | $126.62M | $106.39M | $120.81M | $57.52M |
| Low Forecast | $87.85M | $41.28M | $36.95M | $33.05M | $31.07M | $29.54M | $26.06M | $23.34M | $22.09M | $21.94M | $18.02M | $14.62M | $12.65M | $14.69M | $9.22M | $6.58M | $-104.70K | $6.19M | $6.04M | $114.49M | $29.91M | $26.86M | $90.04M | $75.45M | $81.75M | $26.27M | $65.47M | $55.01M | $80.54M | $38.35M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.08% | 1.48% | 1.70% | 2.28% | 1.74% | - | 3.66% | -361.36% | 3.35% | 3.70% | 0.22% | 1.06% | 1.04% | 0.31% | 0.39% | 0.33% | 1.01% | 0.38% | 0.44% | 0.32% | 0.65% |
Agios Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $25.14M, based on 3 Wall Street analysts, with a range of $22.09M to $32.51M. The forecast indicates a -2.64% fall compared to AGIO last annual SG&A of $25.82M (Sep 23).
Agios Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 3 | 6 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 8 | 5 | 5 | 10 | 7 | 4 | 4 | 8 | 5 | 11 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | $-1.64 | $-1.51 | $-1.29 | $3.14 | $-1.32 | - | $-1.62 | $-1.82 | $-1.56 | $-1.41 | $26.95 | $-1.41 | $-1.43 | $-1.31 | $-0.59 | $-1.60 | $-1.81 | $-1.87 | $-1.59 | $-1.58 | $-1.63 |
| Avg Forecast | $-1.41 | $-1.59 | $-1.69 | $-1.63 | $-1.77 | $-1.71 | $-1.60 | $-1.65 | $-1.65 | $-1.70 | $-1.56 | $-1.70 | $-1.37 | $-1.76 | $-1.75 | $-1.74 | $-1.66 | $-1.57 | $-1.33 | $-1.29 | $-1.31 | $-1.36 | $-1.36 | $-1.67 | $-1.70 | $-1.80 | $-1.70 | $-1.75 | $-1.76 | $-1.61 |
| High Forecast | $-1.19 | $-1.34 | $-1.42 | $-1.38 | $-1.49 | $58.49 | $-1.35 | $-1.39 | $-1.39 | $-1.39 | $-1.32 | $-1.43 | $-1.15 | $-1.49 | $-1.75 | $-1.21 | $-1.15 | $-1.09 | $-0.92 | $-0.90 | $-0.91 | $-0.94 | $-0.95 | $-1.15 | $-1.18 | $-1.25 | $-1.18 | $-1.21 | $-1.41 | $-1.29 |
| Low Forecast | $-1.95 | $-2.20 | $-2.33 | $-2.26 | $-2.44 | $-61.91 | $-2.21 | $-2.28 | $-2.28 | $-1.79 | $-2.16 | $-2.35 | $-1.89 | $-2.44 | $-1.75 | $-2.82 | $-2.70 | $-2.54 | $-2.15 | $-2.09 | $-2.12 | $-2.20 | $-2.21 | $-2.70 | $-2.75 | $-2.91 | $-2.75 | $-2.84 | $-2.11 | $-1.93 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.96% | 0.97% | 0.76% | -2.29% | 0.75% | - | 0.93% | 1.09% | 1.00% | 1.06% | -20.85% | 1.08% | 1.05% | 0.96% | 0.35% | 0.94% | 1.01% | 1.10% | 0.91% | 0.90% | 1.01% |
According to 3 Wall Street analysts, Agios Pharmaceuticals's projected average Quarter EPS for Mar 23 is $-1.70, with a low estimate of $-2.35 and a high estimate of $-1.43. This represents a -154.18% decrease compared to AGIO previous annual EPS of $3.14 (Dec 22).
Agios Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PLRX | Pliant Therapeutics | $12.00 | $39.71 | 230.92% | Buy |
| ARVN | Arvinas | $25.05 | $75.36 | 200.84% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| RLAY | Relay Therapeutics | $7.60 | $19.50 | 156.58% | Buy |
| BDTX | Black Diamond Therapeutics | $6.19 | $14.75 | 138.29% | Buy |
| KALV | KalVista Pharmaceuticals | $11.14 | $26.00 | 133.39% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| MGTX | MeiraGTx | $4.25 | $9.00 | 111.76% | Buy |
| SNDX | Syndax Pharmaceuticals | $19.12 | $36.00 | 88.28% | Buy |
| KROS | Keros Therapeutics | $56.98 | $105.00 | 84.28% | Buy |
| CGEM | Cullinan Oncology | $17.95 | $32.00 | 78.27% | Buy |
| CCCC | C4 Therapeutics | $6.44 | $11.33 | 75.93% | Hold |
| COGT | Cogent Biosciences | $10.63 | $18.50 | 74.04% | Buy |
| MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
| MRSN | Mersana Therapeutics | $2.11 | $3.00 | 42.18% | Buy |
| BMRN | BioMarin Pharmaceutical | $84.90 | $111.41 | 31.22% | Buy |
| IDYA | IDEAYA Biosciences | $37.46 | $46.13 | 23.14% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
| NRIX | Nurix Therapeutics | $24.80 | $27.57 | 11.17% | Buy |
| KYMR | Kymera Therapeutics | $46.08 | $51.10 | 10.89% | Buy |
| AGIO | Agios Pharmaceuticals | $46.69 | $47.50 | 1.73% | Buy |
| ANAB | AnaptysBio | $40.33 | $36.33 | -9.92% | Buy |
AGIO Forecast FAQ
Is Agios Pharmaceuticals a good buy?
Yes, according to 5 Wall Street analysts, Agios Pharmaceuticals (AGIO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 80.00% of AGIO's total ratings.
What is AGIO's price target?
Agios Pharmaceuticals (AGIO) average price target is $47.5 with a range of $32 to $70, implying a 1.73% from its last price of $46.69. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Agios Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for AGIO stock, the company can go up by 1.73% (from the last price of $46.69 to the average price target of $47.5), up by 49.93% based on the highest stock price target, and down by -31.46% based on the lowest stock price target.
Can Agios Pharmaceuticals stock reach $70?
AGIO's average twelve months analyst stock price target of $47.5 does not support the claim that Agios Pharmaceuticals can reach $70 in the near future.
What is Agios Pharmaceuticals's current price target trend?
1 Wall Street analyst forecast a $56 price target for Agios Pharmaceuticals (AGIO) this month, up 19.94% from its last price of $46.69. Compared to the last 3 and 12 months, the average price target increased by 18.87% and increased by 11.91%, respectively.
What are Agios Pharmaceuticals's analysts' financial forecasts?
Agios Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $38.76M (high $47.55M, low $34.66M), average EBITDA is $-101M (high $-82.926M, low $-122M), average net income is $-375M (high $3.09B, low $-3.885B), average SG&A $123.01M (high $150.9M, low $110M), and average EPS is $-6.73 (high $54.27, low $-68.846). AGIO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $71.4M (high $92.32M, low $62.75M), average EBITDA is $-42.84M (high $-37.647M, low $-55.389M), average net income is $-359M (high $-303M, low $-496M), average SG&A $226.6M (high $292.97M, low $199.13M), and average EPS is $-6.325 (high $-5.328, low $-8.734).
Did the AGIO's actual financial results beat the analysts' financial forecasts?
Based on Agios Pharmaceuticals's last annual report (Dec 2022), the company's revenue was $14.24M, which missed the average analysts forecast of $15.42M by -7.66%. Apple's EBITDA was $-527M, beating the average prediction of $-208M by 153.59%. The company's net income was $-74.555M, missing the average estimation of $-380M by -80.39%. Apple's SG&A was $121.67M, beating the average forecast of $48.94M by 148.61%. Lastly, the company's EPS was $-1.36, missing the average prediction of $-6.62 by -79.46%. In terms of the last quarterly report (Sep 2023), Agios Pharmaceuticals's revenue was $7.4M, missing the average analysts' forecast of $7.53M by -1.69%. The company's EBITDA was $-101M, beating the average prediction of $-4.516M by 2134.41%. Agios Pharmaceuticals's net income was $-91.324M, missing the average estimation of $-96.706M by -5.57%. The company's SG&A was $25.82M, beating the average forecast of $23.88M by 8.11%. Lastly, the company's EPS was $-1.64, missing the average prediction of $-1.702 by -3.67%